Topics

GEn1E gets exclusive rights to UMB's p38a kinase inhibitor program

14:40 EST 13 Feb 2020 | Elsevier Business Intelligence

GEn1E Lifesciences Inc. received exclusive global rights to the University of Maryland, Baltimore’s specific and function s...

Original Article: GEn1E gets exclusive rights to UMB's p38a kinase inhibitor program

NEXT ARTICLE

More From BioPortfolio on "GEn1E gets exclusive rights to UMB's p38a kinase inhibitor program"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...